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The nine membrane-bound isoforms of adenylyl cyclase (AC), via synthesis of the
signaling molecule cyclic AMP (cAMP), are involved in many isoform specific physiological
functions. Decreasing AC5 activity has been shown to have potential therapeutic benefit,
including reduced stress on the heart, pain relief, and attenuation of morphine dependence and
withdrawal behaviors. However, AC structure is well conserved, and there are currently no
isoform selective AC inhibitors in clinical use.
P-site inhibitors inhibit AC directly at the catalytic site, but with an uncompetitive or
noncompetitive mechanism. Due to this mechanism and nanomolar potency in cell-free
systems, attempts at ligand-based drug design of novel AC inhibitors frequently use P-site
inhibitors as a starting template. One small molecule inhibitor designed through this process,
NKY80, is described as an AC5 selective inhibitor with low micromolar potency in vitro. P-site
inhibitors reveal important ligand binding “pockets” in the AC catalytic site, but specific
interactions that give NKY80 selectivity are unclear. Identifying and characterizing unique
interactions between NKY80 and AC isoforms would significantly aid the development of
isoform selective AC inhibitors. I hypothesized that NKY80’s selective inhibition is conferred
by AC isoform specific interactions with the compound within the catalytic site.
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A structure-based virtual screen of the AC catalytic site was used to identify novel small
molecule AC inhibitors. Identified novel inhibitors are isoform selective, supporting the
catalytic site as a region capable of more potent isoform selective inhibition. Although NKY80
is touted commercially as an AC5 selective inhibitor, its characterization suggests strong
inhibition of both AC5 and the closely related AC6. NKY80 was also virtually docked to AC to
determine how NKY80 binds to the catalytic site. My results show a difference between
NKY80 binding and the conformation of classic P-site inhibitors. The selectivity and notable
differences in NKY80 binding to the AC catalytic site suggest a catalytic subregion more
flexible in AC5 and AC6 that can be targeted by selective small molecule inhibitors.
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Lay Abstract
Adenylyl cyclase (AC) is a protein that produces the signaling molecule cyclic AMP
(cAMP). There are nine AC isoforms at cell membranes that, despite being structurally similar
and found in various tissue types, have many isoform specific physiological roles. AC5
activity, for example, has been implicated in pain sensation, effects of morphine and other
opioids, and heart function. This makes AC5 inhibition desirable as a potential treatment to
block chronic pain, lessen the dependence and withdrawal effects of opioids, or protect against
chronic heart failure. However, isoform specific inhibition would be important for AC
inhibiting drugs in order to limit the number of potential side effects.
There are AC inhibitors used in research that are not suitable for drug development
because they are not potent enough, specific enough, and/or are unable to enter cells. This
project aimed to characterize isoform selective AC inhibition with a known isoform selective
inhibitor and predict how it binds to the catalytic site of AC differently from nonselective
inhibitors. Novel AC inhibitors with some isoform selectivity were identified in a virtual screen
predicting the binding of small drug-like molecules to the AC catalytic site. Additionally,
although being commercially sold as an AC5 specific inhibitor, the small molecule NKY80 was
shown to inhibit AC5 as well as the closely related AC6 more potently than the other seven
isoforms. Virtual binding of NKY80 to AC predicted that NKY80 has a unique interaction
within catalytic site that classical nonselective AC inhibitors do not have so consistently. We
propose this region is more flexible in AC5 and AC6, explaining NKY80’s selectivity and
allowing for targeting of this region to develop more selective AC inhibitors.
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Chapter 1
Introduction

1

Adenylyl Cyclase Function and Structure
The primary function of adenylyl cyclase (AC) is to produce the signaling molecule
cyclic AMP (cAMP), an important 2nd messenger in cell signaling[1]. Production of cAMP
occurs through conversion of the cellular energy storage molecule adenosine triphosphate
(ATP) into cAMP and pyrophosphate, with cAMP then being free to target downstream
signaling proteins. There are nine mammalian membrane-bound isoforms of AC (AC1-9), as
well as a soluble mammalian form (sAC). This sAC is similar to the bacterial cyclase
predecessor of mammalian AC[2].
Global structure of the membrane-bound AC isoforms is well conserved. Basic
organization involves a cytosolic N-terminus (NT) and two other cytosolic domains (C1 and
C2) separated by a pair of 6-transmembrane helices[3](Figure 1). The NT domain has sequence
and length that varies widely amongst the isoforms. The NT variability allows for some
mechanisms of isoform specific regulation. This includes scaffolding actions that may facilitate
signal transduction. For example, it has been shown that the AC5 NT anchors heterotrimeric G
proteins[4]. The two C1/C2 cytoplasmic domains are 40% similar in sequence,
pseudosymmetrical, and form the catalytic area where ATP binds and synthesis of cAMP takes
place[5]. These C1/C2 domains are also where various intracellular regulators such as
heterotrimeric G proteins interact with AC[6, 7].

AC Regulation
Signaling proteins that similarly regulate all AC isoforms are rare; one notable
exception is the heterotrimeric G protein subunit Gsα, which stimulates all AC isoforms[8-10].
AC isoform specific function is due to differences in tissue expression patterns (Table 1),
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Figure 1: Schematic of AC Structure.
regulation, and organization of signaling by scaffolds such as A-kinase anchoring proteins
(AKAPs). Some notable differences in regulation allow for organization of AC1-9 into groups.
AC 1, 3, and 8 are noted for their stimulation by calcium-stimulated calmodulin; AC 2, 4, and 7
are characterized by considerable conditional stimulation by Gβγ; AC 5 and 6 both have
sensitive, micromolar level inhibition by free calcium; and AC9 is in a unique class by itself,
including insensitivity to the AC activator forskolin[11]. Since C1 and C2 AC domains form
the ATP binding site where cAMP production takes place, most regulators of AC directly or
indirectly modify this catalytic cleft in order to modulate AC activity. The same signaling
protein can also regulate AC isoforms differentially; for example, Gβγ stimulates AC 2/4/5/6/7,
but inhibits AC 1/3/8[12, 13].
Metal ions such as Mn2+, Ca2+, and Mg2+ also have significant effects at the catalytic
site on cAMP production[14]. AC catalyzes phosphoryl transfer by a metal ion mechanism
involving Mn2+ or Mg2+. This metal requirement is similar to that for DNA polymerase
function. Conversely, Ca2+ and Zn2+ can inhibit AC[15, 16].
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Forskolin is a diterpene derived from the root of the plant Coleus forskohlii[17]. It is
able to clearly stimulate activity of all the membrane-bound AC isoforms except AC9[11, 18].
A single forskolin molecule binds at the interface of the C1 and C2 domains[19]. Due to the
C1/C2 pseudosymmetrical structure, the forskolin binding pocket is structurally related to the
ATP-binding active site. AC9 is missing a key residue within this forskolin-binding pocket that
when mutated can elevate forskolin sensitivity to the level exhibited by the other AC
isoforms[20]. Gsα and forskolin are also capable of simultaneous stimulation of AC; whether
this stimulation is synergistic or additive is isoform specific[18].
AC5 and 6 are very closely related AC isoforms. They are both stimulated by Gsα and
Gβγ[12] and inhibited by Ca2+[21] and PKA[22]. Neither is directly inhibited by Goα, although
it has been shown that there is a mechanism of indirect inhibition of AC5 or AC6 by Goα
signaling that could be blocked by antibodies targeting Goα[23]. The known differences
between regulation of AC5 and AC6 are typically subtle. For example, Gsα stimulated activity
of either isoform is inhibited by Giα, but basal activity of AC5 is also inhibited by Giα while
AC6 basal activity is not[24]. Also, AC5 is stimulated by PKC-α and -ζ[25], while AC6 is
inhibited by PKC-δ and -ε[26, 27]. Gqα signaling can enhance AC6 activity, but not that of
AC5, within intact cells by a calcium/calmodulin dependent mechanism[28]. Both isoforms
thus have numerous stimulatory and inhibitory inputs to control cAMP levels.

AC Roles in Physiology
The various AC isoforms are involved in many physiological phenomena, with isoform
specific roles that are sometimes unclear. Physiological roles of AC cannot solely be explained
by tissue distribution. Each AC isoform has a unique tissue expression pattern, but multiple
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isoforms are found in nearly all cell types[29]. Originally, the AC/cAMP pathway was
characterized by its role in glycolysis and glucose metabolism[30]. Over time, other
physiological roles have been identified as well; reviews have been produced that catalogue
evidence for various isoform specific functions[6], while a somewhat briefer summary will be
given here (Table 1). Learning, memory, and synaptic plasticity involve the closely related
isoforms AC1 and AC8[31-36]. AC2, AC4, and AC7 have few clear physiological roles at this
point, although evidence suggests AC7’s involvement in ethanol dependency[37] and immune
cell function[38]. AC3 is involved in olfactory function[39, 40], as well as regulation of renal
filtration[41]. AC3 and sAC both appear to have roles in the testes for sperm production and
function[42-44]. AC9 has suggested roles in ion channel mediated repolarization of the
heart[45] and immune cell migration[46].
Of the AC isoforms, AC5 has by far the widest variety of identified physiological
functions, typically being described by AC5 knockout mouse models. AC1 and AC5 have been
implicated in different aspects of pain response, with AC5 mouse knockouts having attenuated
responses to both mechanical and inflammatory pain[47]. These mice are characterized by
limited mechanical and thermal response to normal stimuli in neuropathic pain models.
Conversely, pharmacological stimulation of the AC/cAMP pathway increased sensitivity to the
inflammatory pain response[48]. AC5 also has been shown, along with AC1, AC6, and AC8, to
have an ability for sensitized stimulation. Sensitized stimulation of AC5 occurs through
receptor-coupled Gsα stimulation following prolonged inhibition by receptor-coupled Giα
protein. Such sensitized activation has been shown with prolonged stimulation of various Giαcoupled GPCRs, including D2 dopamine and μ-opioid receptors[49-52]. Tolerance, reward and
physiological dependence, and withdrawal symptoms of the opiates are functions where these
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receptors have been strongly suggested to play roles. For AC5, this sensitized stimulation
appears to also be involved in opiate dependency and withdrawal behaviors, as the effects of
morphine were attenuated in AC5 knockout mice[53]. AC5 has also been shown to be
involved in motor coordination, with AC5 mouse knockouts developing Parkinson’s-like
tremors and other motor dysfunctions[54]. All three of these physiological functions are
regulated to some degree in the brain by the striatum, where AC5 expression is strongly
enriched and is the principal signaling node for D1 and D2 dopamine receptors[55].
6

Additionally, although multiple AC isoforms are expressed in the heart, AC5 and AC6
are most predominantly expressed[56] and have the most clearly demonstrated cardiac
functions at this time. A role of the AC/cAMP signaling pathway in heart failure has been
established by models of increased expression of signaling proteins upstream and downstream
of AC resulting in cardiomyopathy[57-59]. The primary treatment of choice for individuals that
are at high risk for chronic heart failture is β-blockers, consistent with significant involvement
of cAMP signaling pathways in cardiac dysfunction[60].
Both AC5 and AC6 are expressed equally in the neonatal heart but AC5 is dominant in
the adult heart[61]. Other work has shown AC5 expression mainly in the ventricle while AC6
was in both the ventricle and atria[62]. Thus, it is likely AC5 and AC6 roles in cardiac
contraction differ. Disruption of AC5 under thoracic banding simulated stress conditions is
protective against heart failure[63]. However, the critical functions of AC5 in the heart are
murky as both sympathetic and parasympathetic cardiac regulations are affected in AC5
knockout mice[64]. This includes a complete loss of acetylcholine-mediated Giα inhibition and
a significant reduction in Ca2+-mediated inhibition of cAMP production consistent with reduced
effects of muscarinic signaling. AC5 loss also desensitizes cardiomyocytes to catecholamine
stress, preventing cardiac apoptosis that would otherwise result[65]. This apoptotic reduction
may underlie the reduced cardiac stress following aortic banding in knockout mice[63]. AC5
knockout mice also have an increased lifespan and are protected against age-induced
cardiomyopathy[66]. This phenotype includes cardiac hypertrophy, apoptosis, and reduced
function. Some mouse models for AC5 loss also show increased basal left ventricular function,
but decreased responsiveness to beta-adrenergic stimulation that suggests a higher threshold for
increasing cAMP signaling over basal levels[67].
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History of AC Inhibitors
With all of these physiological functions associated with the AC/cAMP signaling
pathway, it is not surprising that the pathway is an attractive target for drugs to modulate these
functions. As a result, many drugs have been identified that target cAMP signaling[68].
Salmeterol is a partial agonist of the β2-adrenergic receptor, increasing cAMP production to
increase circulation useful in the treatment of asthma. Theophylline is a phosphodiesterase
inhibitor and adenosine receptor antagonist also used as an asthmatic treatment by maintaining
elevated cAMP, albeit as a less frequently used treatment. Beta-blockers decrease cAMP and
are used as treatments for various heart conditions, such as metoprolol for hypertension and
heart failure. Morphine is a µ-opioid receptor agonist that decreases cAMP and, in turn, inhibits
pain sensation. Various dopamine receptor agonists and antagonists modulate cAMP activity
downstream as therapeutics for schizophrenia, Parkinson’s disease, and nausea.
However, these therapeutics target upstream GPCRs or downstream regulators of
cAMP concentration. Direct control of cAMP production by targeting AC activity has been a
more difficult target. The structural similarity and overlapping tissue expression of AC
isoforms provide great risk for nonspecific effects. Since AC is an enzymatic protein with
transmembrane and cytoplasmic domains, the lack of extracellular domains such as those
targeted by ligands on GPCRs mean an AC drug must be capable of passing through the plasma
membrane, which has severely limited the kind of molecules that progress past cell-based
systems and preclinical animal models. Some AC inhibitor prodrug packages have been
attempted to circumvent this issue[69, 70]. However, the current state is that there are no
isoform specific AC inhibitors in clinical use.
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That being said, there has been progress in identifying AC isoforms that would be
desirable as targets if they could be selectively inhibited. Since it has been shown that AC5,
AC1, and AC8 are involved in inflammatory/neuropathic pain, but only AC5 does not cause
any major defects in knockout mouse models, AC5 inhibitors have promise as analgesics. Since
negative side effects due to compensatory mechanisms are induced by long-term opioid use in
patients with chronic pain, AC5 selective inhibitors for patients could also be more viable for
long-term treatment. Based on AC5 knockout models, AC5 inhibitors could also act similarly
to beta-blockers in the treatment of heart failure. The predominant expression of AC5 and
closely related AC6 in heart failure combined with their differing effects on cardiac function
requires a selective ligand that would inhibit AC5 but not AC6. The drastic AC5 activity
differences in chronic versus acute heart failure also has to be taken into account for
prospective drug development. It has been suggested that increased cAMP from AC5 activity is
beneficial as a rescue function in acute heart failure, but is clearly detrimental in chronic failure
models. Colforsin daropate hydrochloride is a direct activator of AC5 (with AC6 potency
unknown)[71]. Its effects include coronary vasodilation[72], and the activator is an approved
treatment in Japan for acute heart failure[73].
In research, two distinct classes of small molecule AC inhibitor are commonly among
those utilized. Examples of these inhibitor classes and some notable inhibitors derived from
them are shown in Figure 2. One of these classes is P-site inhibitors, which bind in the AC
catalytic site and decrease activity through uncompetitive inhibition[74, 75]. The original P-site
inhibitors, which we will call classic P-site inhibitors, are adenosine nucleotide analogs with a
phosphate or polyphosphate group at the 3’ position of a ribose ring. These inhibitors are more
potent on activated forms of AC versus the basal state, forming a product-like transition state
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Figure 2: Notable Small Molecule AC Inhibitors.
with pyrophosphate to prevent further ATP binding[76]. Although most of the classic P-site
inhibitors were synthetically made, some are naturally occurring variants of ADP and ATP[77].
More potent inhibitors, such as adenosine 3′-polyphosphates (i.e. 2′,5′-dideoxy-3′-ATP), bind in
the absence of pyrophosphate with the aid of the 3′-phosphates, increasing the affinity of these
10

inhibitors by 100- to 1,000-fold[78, 79]. This conformation is also produced by the
noncompetitive ATP analog 2’,3’-dideoxy-5’-ATP, currently the most potent AC inhibitor at a
Ki of 16nM for rat brain AC[80]. Although most classic P-site inhibitors lack isoform
selectivity, there are some exceptions. It has been shown that 2’-deoxy-3’-AMP is mildly
selective for AC1 over AC2 and AC6[81]. Also, AC9 is insensitive to 2′-deoxy-3′-AMP [81].
In general, however, P-site inhibitors that are not products of inhibitor optimization
experiments are not greatly selective against certain isoforms. P-site based inhibitors
nonetheless are extremely direct and potent inhibitors; these compounds typically have
affinities of nanomolar concentration.
The other predominant class of direct small molecule AC inhibitors is the MANTnucleotide inhibitors. One such example is MANT-GTP, which has a Ki of 53nM in Sf9 cyclymphoma cell membranes[82]. MANT-GTP binds in the ATP-binding site with a nucleotide
in reverse orientation compared to ATP analogs such as P-site inhibitors[83, 84]. Interestingly,
published research suggests that MANT-GTP and similar MANT-nucleotides show potential
for designing isoform selective compounds that target the AC catalytic site despite the
structural similarity of AC isoforms[83, 85]. These MANT-GTP screens suggested inhibitor
affinity was more dependent on the ribose and polyphosphate components of such small
molecule AC inhibitors, not necessarily the base component. Thus, non-nucleotide based
inhibitors able to modulate AC activity directly at the catalytic site are theoretically possible at
therapeutically desirable potency levels. The crystal structure of MANT-GTP with AC also
suggests catalytic site flexibility, with the movement of helices to accommodate the MANT
group in a “C” pocket that can accommodate hydrophobic interactions. Crystallized P-site
inhibitors show only two subregions of the ATP binding site; an “A” pocket where hydrogen
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bonding to the purine group takes place, and a “B” pocket including the two metal ion binding
sites and typically containing metal-phosphate interactions. MANT-GTPγS introduced into
whole-cell mouse cardiomyocytes by patch pipette has been used to attenuate L-type calcium
channel currents that was presumably through inhibition of coupled AC5[86].

Significance of Proposed Research
Validation of isoform selective small molecule AC inhibitors in preclinical animal
models is a stage of therapeutic development rarely reached. The most significant obstacle is
generating small molecule inhibitors with sufficient potency, selectivity, and therapeutic
potential combined. One small molecule inhibitor that resulted from searching for these
characteristics in a compound derived from P-site inhibitors, NKY80, is described as an AC5
selective inhibitor with low micromolar potency in vitro. Classic small molecule AC inhibitors
have revealed important ligand-binding “pockets” in the AC catalytic site, but what specific
interactions in these regions give NKY80 selectivity is currently unclear.
Identifying and characterizing unique interactions between NKY80 and AC isoforms
could be used to determine isoform specific differences in the interaction of the well conserved
catalytic site with regulatory molecules, and as a result significantly aid the development of
isoform selective AC inhibitors with therapeutic potential. I hypothesize that unique isoform
specific interactions between the AC catalytic site and NKY80 explain the small molecule’s
selective inhibition profile.
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Chapter 2
Materials and Methods
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Virtual Ligand Docking
Searching for novel directly binding AC inhibitors was performed by using Glide
docking software from Schr dinger to dock ligands specifically to the catalytic ATP binding
site of AC. Both known P-site inhibitors and 35,000 compounds from the generic ChemBridge
library of drug-like small molecules that follow Lipinski’s rule of five were used as ligand
libraries. These libraries were docked to a model of the AC catalytic site adapted from crystal
structure of the AC C1/C2 domains bound with the inhibitor 2’,3’-dd-ATP (PDB ID 1CJT)[16].
This model had waters, forskolin, Gαs protein, Mg2+ ion, Cl- ion, and buffer molecules
removed, leaving only the AC C1 and C2 domains. Ligand 3D structures were prepared,
including unprotonated state and creation of stereoisomers, using Schr dinger’s LigPrep
software. Docking was restricted to the ATP binding region of the catalytic cleft. Hydrogen
bonds were defined by a donor-acceptor distance cutoff of 3.5 Å and a donor-hydrogenacceptor angle between 150° and 180°. ChemBridge ligands were ranked based on the Glide
predicted energy score in kcal/mol and most energetically favorable binding pose.
AutoDock 4.2 was used to dock known P-site inhibitors and NKY80 to the entire
structure of the AC catalytic site model from crystal structure 1CJT. Docking to the entire AC
structure was chosne to test if AutoDock correctly predicts P-site inhibitor binding to the
catalytic site in an unbiased manner, as well as to provide a comprehensive prediction of the
NKY80 binding site. The value of such a “blind docking” procedure has been demonstrated
previously[87]. Briefly, small molecule inhibitor ligands were prepared with AutoDock tools,
creating a nonpolar atomic charge sum and calculating the Gasteiger charges and torsions[88,
89]. AutoDock 4.2 was then used to dock the ligands onto a grid large enough to encompass the
entire surface of the AC catalytic site from crystal structure 1CJT with 0.375 Å grid spacing. A
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population size of 150, with 2 Å clustering cutoff, 10,000 LGA hybrid with 256 runs was used.
Predicted poses were analyzed in terms of their energetic binding potential. Hydrogen bonds
were defined as described for Glide docking. Van der Waals contacts were defined by a carboncarbon distance cutoff of 5.0 Å. Potential poses were predicted and ranked based on the
predicted binding affinities.
The free ICM-Browser available from Molsoft L.L.C. was used to visually inspect
predicted conformations of ChemBridge small molecules during virtual screening. In addition,
VMD Viewer 1.9 from the Theoretical and Computational Biophysics Group at the University
of Illinois at Urbana-Champaign was used for visual analysis of the known inhibitor docking
results, and for image rendering.

AC Sequence Alignment
Alignment of two or more AC sequences using BLAST (http://blast.ncbi.nlm.nih.gov/)
was utilized to compare C1 and C2 domains of various AC isoforms. The primary sequences of
the C1/C2 domains used in a crystallized AC structure (PDB ID 1CJT) were aligned with the
corresponding C1/C2 sequences of human AC1-9.

Cell Line Maintenance
Sf9 insect cells were maintained with SF-900 II SFM media contained in cell
suspension flasks. Cells were passaged to maintain a concentration of log phase cells between
0.5 X 106 and 5.5 X 106 cells/ml. Cell incubation was in a 27°C shaker at 150rpm.
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HEK293 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) with
10% fetal bovine serum and 1% penicillin/streptomycin on 10cm dishes in a 37°C, 5% CO2
incubator.

Sf9 AC Expression
Baculoviruses were amplified for 5-7 days using 500µl of storage virus stock with 50ml
of Sf9 cells in log phase in SF-900 II SFM media with 50 μg/ml gentamicin at a concentration
of 1.5-2 X 106 cells/ml to produce a baculovirus working stock with a minimum titer of 1 X 107
pfu/ml. 25ml of the appropriate AC isoform baculovirus was used to infect 1 liter of Sf9 cells at
a concentration of 1.5-2 X 106 cells/ml. After 48 hours of infection, Sf9 cells were harvested
by centrifugation at 1000 g for 10 minutes at 4°C.

Sf9 Membrane Preparation
Harvested cells were suspended in 600ml of cold lysis buffer consisting of 50 mM
NaHEPES (pH 8.0), 0.1 mM EDTA, 3 mM MgCl2, 10 mM β-mercaptoethanol, 100 mM NaCl,
10 μM GDP, 0.02 mg/ml phenylmethylsulfonyl fluoride, 0.03 mg/ml leupeptin, 0.02 mg/ml 1chloro-3-tosylamido-7-amino-2-heptanone, 0.02 mg/ml L-1-tosylamido-2-phenylethyl
chloromethyl ketone, and 0.03 mg/ml lima bean trypsin inhibitor. Cells were lysed by nitrogen
cavitation at 500 PSI, 4°C for 30 min. Cell lysates were centrifuged at 750g for 10 min at 4°C
to remove intact cells and nuclei. The supernatants were centrifuged at 100,000g for 30 min at
4°C. Resulting pellets were suspended in 300 ml of buffer consisting of 50 mM NaHEPES (pH
8.0), 3 mM MgCl2, 10 mM β-mercaptoethanol, 50 mM NaCl, 10 μM GDP, and proteinase
inhibitors as above, dounce homogenized, and centrifuged again at 100,000g for 30 min at 4°C.
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Resulting pellets were then resuspended. Resuspended Sf9 membrane pellets had concentration
determined by Bradford assay, with membranes then immediately frozen in liquid nitrogen and
stored at -80°C in one-use aliquots for future adenylyl cyclase activity assays (see below).

HEK AC Transfection
HEK293 cells were seeded at 3 X 106 cells per 10cm dish in DMEM with 10% FBS
approximately 24 hours before transfection. On the next day, medium was replaced with fresh
DMEM (no FBS or penicillin/streptomycin). The appropriate plasmids (10ug DNA total per
plate) and Lipofectamine 2000 transfection reaction (3µl per 1ug DNA, or 30µl per plate) were
separately incubated in OPTI-MEM medium for 5 minutes, and then in combination for an
additional 20 minutes. The transfection solution was then added dropwise to the appropriate
cell dishes. Cells were incubated at 37°C for 4-6 hours. The media was then replaced with
DMEM + 10% FBS and returned to the incubator. In total, the cells were incubated for
approximately 40 hours before harvesting.

HEK Membrane Preparation
Following 40 hour cell transfections (see above), HEK293 cells were rinsed with cold
PBS and scraped from 10cm dishes with cold PBS + protease inhibitors. Cells were then
pelleted by centrifugation at 3000g, 4°C for 5 minutes. Cell pellets were aspirated and
resuspended in 20mM HEPES, 1mM EDTA, 2mM MgCl2, 1mM DTT, 250mM sucrose, and
protease inhibitors. Cells were incubated on ice for 10-30 minutes and then homogenized with
a 2ml dounce homogenizer. Cell homogenates were centrifuged at 1800g, at 4°C for 5 minutes
to pellet nuclei. The supernatants were transferred to firm-walled microfuge tubes and
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centrifuged at 60,000g, 4°C for 20 minutes. The resulting membrane pellet was resuspended in
20mM HEPES, 1mM EDTA, 2mM MgCl2, 1mM DTT, and 250mM sucrose. HEK membrane
concentrations were determined by Bradford assay. Membranes were immediately assayed in
adenylyl cyclase activity assays (see below) or frozen in liquid nitrogen and stored at -80°C in
one-use aliquots for future assays.

Adenylyl Cyclase Activity Assays
As performed and described previously[90], Sf9 or HEK membrane preparations (see
above) were incubated for 10 minutes at 30°C with an AC mix containing {α-32P}ATP and
appropriate activators. The activators used were 50µM forskolin for Sf9 membranes of AC1-7,
100µM calcium and 300µM calmodulin for HEK membranes of AC8, and 300nM Gsα for
HEK membranes of AC9. Reactions were stopped with a solution of 2.5% SDS, 50mM ATP,
and 1.75mM cAMP. Nucleotides in each reaction sample were then separated by column
chromatography to isolate {32P}cAMP product produced by AC membranes during the reaction
period, using {3H}cAMP to monitor column recovery rates. Separated samples were collected
in scintillation vials with scintillation fluid. Production of cAMP was measured by scintillation
counting using a dual dpm program to count {3H}cAMP and {32P}cAMP isolated from each
sample.
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Chapter 3
Virtual Docking of AC Catalytic Site
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Derivation of AC Docking Target
Crystal structures of AC have been obtained from purified C1/C2 catalytic domains of
AC, as the N-terminus and membrane-spanning domains are too unstable for crystallization.
These purified C1/C2 domains were originally produced to have a soluble, membrane-free
setting for characterizing C1/C2 domain interactions with each other and/or AC regulators[91].
In solution, these domains are capable of reproducing conversion of ATP into cAMP[92, 93].
The original crystallization producing an AC structure model used a pair of rat AC2 C2
domains with the activator forskolin[94], but this cytosolic domain combination was
catalytically dead. The first active crystallized structure, consisting of canine AC5 C1 and rat
AC2 C2 domains, was stable enough to form a crystallized structure with bound activators
forskolin and Gsα[5]. This also clarified the pseudosymmetrical nature of AC catalytic
structure, including its mechanism of regulation by heterotrimeric G protein α subunits.
Exploration of the method of metal catalysis of AC activity by crystallization of the AC
catalytic core followed[16]. These 5C1/2C2/Fsk/Gsα catalytic structures showed variants of
“open” conformations conducive to active AC, but not the inactive “closed” conformations that
would be expected to occur with a bound inhibitor. Subsequent crystallization of AC catalytic
cores aimed to identify such inactive conformations. Such crystallizations included the
conformations of P-site inhibitors binding to the ATP-binding site despite their typically
uncompetitive inhibitory mechanism[76], the competitive MANT-nucleotide inhibitors binding
at the same site[84, 85], and the binding of free calcium ions to inhibit AC5 and AC6[95].
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In order to perform a virtual screen against AC, we used PDB 1CJT, which is an AC
structure comprised of 5C1/2C2/Fsk/Gsα co-crystallized with one Mg2+ and one Mn2+ in the
metal ion binding sites, and the ATP analog 2’,3’-dideoxy-5’-ATP[16]. Modification of this
crystal structure into a computational target began with the removal of all waters and the Gsα
protein in order to focus on interactions between ligands and the C1/C2 domains of AC. Two
metal ions are typically seen in crystallized structures, but it is questionable that both are
required for catalysis; experiments suggest complexes of P-site inhibitors with one metal[96].
Additionally, in terms of computational docking, metal ions are typically a major charge-based
energetic demand that is favored over other interactions that may have more importance for
ligand-target specificity. Thus, to minimize false positives only binding to the metal ions, only
the Mn2+ metal that interacts with the γ-phosphate of 2’,3’-dd-ATP was kept. The crystal
structure in the area within 5 Å of this inhibitor’s bound conformation was confirmed by
sequence alignment to be identical to human AC5 (Figure 3). This is despite the C2 domain
being from AC2, as the catalytic region is so homologous.

Figure 3: Alignment of Catalytic Site of Crystal AC Structure and Human AC5.
Residues within 5 Å of the crystallized conformation of 2',3'-dd-ATP in PDB ID 1CJT
are indicated in red.
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Validation of Docking to AC Target
It had to be confirmed that it was possible to replicate the known crystal binding
position of 2’,3’-dd-ATP with the binding position predicted by virtual docking. In order to
justify use of the modified version of crystallized AC structure as a computational docking
target, 2’,3’-dd-ATP was thus redocked with Glide and AutoDock. Results show that the
predicted docking pose that was produced for 2’,3’-dd-ATP closely replicates the crystallized
binding conformation (Figure 4). This demonstrates the ability to replicate the known bound
conformation of a small molecule ligand, in this case the inhibitor 2’,3’-dd-ATP, through
virtual docking.

Figure 4: Replication of Binding Conformation of 2',3'-dd-ATP. (A) Chemical structure
of 2',3'-dd-ATP. (B) Overlay of predicted (cyan carbons) and crystallized (grey) binding
conformations of 2',3'-dd-ATP by AutoDock 4.2 docking program. AC C1 domain is
yellow, AC C2 domain is silver, manganese metal ion is orange.
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Docking of P-Site Inhibitors to AC Target
Classic P-site inhibitors all bind to AC similarly, with an adenine or adenine-like group
in the “A” pocket, and a multi-phosphate group in the metal-containing “B” pocket. Other
crystallized structures of AC C1/C2/Gsα/Fsk with classic P-site inhibitors include the
conformations of 2’-deoxy-3’-AMP with pyrophosphate (PDB ID 1CS4) and 2’,5’-dideoxy-3’AMP with triphosphate (PDB ID 1CUL). These P-site inhibitors were previously used in other
crystallized structures of AC to explore the mechanism of P-site regulation[76]. It was of
interest to determine if the developed AC catalytic site target was capable of producing realistic
binding positions for other small molecule inhibitors. Thus, as ligands known to bind to the AC
catalytic site but not included in the 1CJT crystallization, these P-site inhibitors were docked to
the AC target derived from 1CJT. As mentioned, the 1CS4 and 1CUL crystal structures used
pyrophosphate and triphosphate respectively and our docks were with one ligand. Thus we
docked 2’-d-AMP without the pyrophosphate molecule, and docked 2’5’-dd-ATP as an
estimation of 2’,5’-dd-AMP with triphosphate.
Again, the ligand docking produced conformations with adenine-like groups bound to
the “A” pocket and phosphates predictably interacting with the manganese ion in the “B”
pocket (Figure 5). 2’-d-AMP’s highest scoring predicted pose from docking to the 1CJT
structure model overlapped significantly with the crystallized pose for 2’-d-AMP and
pyrophosphate from 1CS4. The largest deviations were the small molecule’s single phosphate
attempting to compensate for the missing pyrophosphate’s metal interactions. Although the
highest scoring pose when docking 2’5’-dd-ATP to the 1CJT-derived model did not have
significant overlap with the crystallized conformation from 1CUL (Figure 5D), the P-site
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inhibitor was targeted to the ATP-binding area of the catalytic domains. Furthermore, the
second highest scored pose did show significant replication of the crystallized position (Figure
5E). The difference in predicted affinity for these two conformations was 0.43 kcal/mol, or
approximately 6.13 attomolar. This is a fairly small difference between two predicted
conformations; thus, the accurately predicted pose with the second highest score can be
considered as a co-highest scored pose. As P-site inhibitors bind similarly, it is worth noting
that all three P-site inhibitors tested have overlap in the same binding pockets across crystal
structures. Thus, predicted binding conformations of analogs for crystallized P-site inhibitors
were able to closely simulate their crystal structure counterparts despite being docked to a
slightly different representation of the AC catalytic region, albeit one with little variation. This
suggests the computational AC catalytic target developed is useful for docking of any P-site
inhibitor like compounds.

Summary
Using the structure of the AC catalytic domains crystallized with the inhibitor 2’,3’-ddATP (PDB ID 1CJT), a target for computational docking to the ATP-binding region of AC was
developed. Redocking of this inhibitor replicated the actual crystallized conformation.
Additionally, attempted docking of P-site inhibitors to the same site closely replicated their
crystallized positions, supporting the developed AC target as a reliable model of the catalytic
site for docking P-site inhibitors and similar compounds.
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Figure 5: P-Site Inhibitors Accurately Docked to Catalytic Site. (A) Chemical structure
of 2'-d-AMP. (B) Overlay of top scoring predicted conformation of 2’-d-AMP (cyan
carbons) and crystallized binding conformation of 2’-d-AMP with pyrophosphate (grey)
by AutoDock 4.2 docking program. (C) Chemical structure of 2',5’dd-AMP. (D) Overlay
of top scoring predicted conformation of 2’,5’-dd-ATP (cyan carbons) and crystallized
binding conformation of 2’,5’-dd-AMP with triphosphate (grey) by AutoDock 4.2
docking program. (E) Overlay of second highest scoring predicted conformation of 2’,5’dd-ATP (cyan) and crystallized binding conformation of 2’,5’-dd-AMP with
triphosphate (grey) by AutoDock 4.2 docking program. For (B), (D), and (E), AC C1
domain is yellow, AC C2 domain is silver, manganese ion is orange.
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Chapter 4
Screening for Novel Inhibitors at AC Catalytic Site
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Current Progress on Small Molecule AC Inhibitor Development
Due to an uncompetitive or noncompetitive inhibitory mechanism and a nanomolar
range of potency in cell-free systems, attempts at ligand-based drug design of novel AC
inhibitors have frequently used P-site inhibitors as a starting point. This is despite their
typically nonselective inhibition of AC isoforms, providing risk for off-target effects. A main
concern regarding P-site inhibitors is the requirement of adenine group and ribose ring[97].
Such a requirement could cause inhibition of enzymes such as DNA polymerases, kinases or
ATP synthases[70]. However, small molecule compounds subsequently developed do not
necessarily have these chemical groups. A notable group of compounds derived from P-site
inhibitors contain an additional metal chelating group and exhibit enhanced AC isoform
selectivity, most notably the AC5 selective PMC-6[98-100].
There is also limited development of small molecules that inhibit AC at the C1/C2
catalytic cleft but do not bind in the ATP-binding site pockets. Examples of these are the
tyrphostins, catechol oestrogens, and calmidazolium, which like PMC-6 chelate metal ions
necessary for catalysis of ATP conversion to cAMP[101, 102].
Only a few in vivo studies have been conducted with small molecules developed from
classic P-site inhibitors. One success story is HTS09836, a patented AC1 inhibitor and orally
available drug. HTS09836 decreases cAMP in human neuronal slices and decreases painrelated behaviors in rat pain models, demonstrating the therapeutic potential of compounds
based on P-site inhibitors[103]. As most P-site inhibitors cannot cross cell membranes and/or
are degraded by adenosine deaminase in intact cells, HTS09836 is a notable exception to the
rule of P-site inhibitors performing poorly in cultured cells or animals.
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High Throughput Virtual Screening for Novel AC Inhibitors
The validated AC docking target derived from PDB 1CJT was used to identify novel
AC inhibitor candidates that lack the issues for therapeutic development that classic P-site
inhibitors do, such as similarity to ATP. Flexible drug-like small molecules from ChemBridge
were docked at the ATP binding site of AC in a structure-based virtual screen. The library
consisted of approximately 35,000 small drug-like ligands. Higher scoring compounds
consistently had interactions in the previously mentioned “A” and “B” pockets of the ATP
binding site. As these compounds were from a generic drug-like molecule library, predicted
hits rarely had chemical groups resembling adenine in the “A” pocket and never had
phosphates in the “B” pocket.

Screening Candidates for Ability to Inhibit AC
A randomly produced list of 300 ligands of the 3500 that scored in the 90th percentile or
above was visually inspected for realism of predicted binding conformation and the existence
of interactions beyond those between the ligand and Mn2+. Based on this subjective inspection
and subsequent clustering of the acceptable predicted hits, 58 highly distinct ligands were
selected for in vitro testing. These compounds were then tested with an AC activity assay to
determine their ability to inhibit AC. Of the compounds that were able to inhibit AC5 at a
concentration of 1mM, an inhibitor concentration of 100µM was tested against AC1, AC2,
AC5, and AC6. Three compounds showed isoform selective inhibition at 100µM; CB-6673567,
CB-7833407, and CB-7921220. All of the compounds selected for testing turned out to have
scored near or above 99th percentile of the structure-based virtual screen (Figure 6).
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Figure 6: Histogram of Top 10% of Scores for ChemBridge Drug-Like Small Molecules.
Top 1% of scores to the left of red line. Glide docking scores from the virtual docking
screen for ChemBridge small drug-like molecules identified as isoform selective AC
inhibitors in vitro are indicated by blue arrows.

Characterizing Selectivity of Novel AC Inhibitors
These three novel inhibitors all decreased AC5 activity by at least 50% at a
concentration of 1mM (Figures 7B, 8B, 9B). While 1mM is a relatively high concentration for
a desirable AC inhibitor, all three compounds had chemical groups not closely related to
adenine or triphopshate groups. Additionally, the requirement of a ribose or ribose-like ring
was not found in these small molecule inhibitors. With the inhibition of AC5 demonstrated by
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these novel molecules, it was then determined whether these inhibitors also had any AC
isoform selectivity properties.
CB-6673567 was able to inhibit AC1 much more strongly than the other AC isoforms at
100µM (Figure 7). Its binding conformation puts a large number of AC residues in close
proximity, but no unique interactions are apparent. CB-6673567 binds in the catalytic cleft,
inserting its pyrazole rings to the “A” pocket. However, the placement of its benzene ring in
free space where presumably there would be water in a biological setting suggests a slightly
different actual conformation for either the inhibitor or the AC structure.
CB-7833407 has a unique binding conformation that makes hydrogen bonds that are
typically seen by ligands in the “A” pocket (Figure 8). The ligand structure is not near any AC
residues while the other end blocks ATP binding via “A” pocket interactions. This appears to
be a shared property of the predicted conformations for CB-6673567 and CB-7833407.
Interactions with AC residues in close proximity to these ligands are not provided outside the
“A” pocket despite the presence of large chemical groups for both ligands that are outside this
pocket. For CB-7833407, this non-pocket chemical structure includes a chlorine atom.
Regarding inhibitory potential, CB-7833407 has isoform selective inhibition of AC2. Thus, the
novel AC isoform inhibitors identified differ in their selectivity profiles.
Lastly, CB-7921220 selectively inhibits AC1 and has a more conventional predicted
binding conformation (Figure 9). Hydrogen bonds are formed in the “A” pocket between CB7921220 and Asp1018 in the as well as Ile1019 of AC. The carboxyl group on the other end of
the ligand is stabilized by close proximity to the Mn2+ ion in the “B” pocket, and to a lesser
extent by a possible interaction with Thr401.

30

The AC1 and AC2 selective inhibition by these novel small molecules support different
binding conformations in the AC catalytic site conferring different isoform selectivity profiles.
Comparison of interacting residues with both CB-6673567 (Figure 7D) and CB-7921220
(Figure 9D) shows significant interaction overlap. However, the majority of this overlap is in
the “A” pocket where any direct inhibitor must bind, and no residues previously characterized
as important for ligand binding are closer than they would be to a typical P-site inhibitor. Thus,
there is no novel interaction that clearly is conferring the observed AC1 selectivity to these
inhibitors. AC residue Thr401 has an oxygen within 3.08 Å of CB-6673567, and its backbone
amide is within 2.89 Å of CB-7921220. Although not yet confirmed, the catalytic site
subregion containing Thr401 may provide the AC1 selectivity seen in these molecules. We
were able to find isoform selective novel AC inhibitors as predicted, although it is surprising
that none of the three had the intended selectivity for AC5 inhibition.

Summary
A large-scale structure-based virtual screen docked small drug-like molecules at the AC
catalytic site with Glide. Using this approach, novel small molecule inhibitors from the
ChemBridge library of drug-like compounds were identified that have little to no similarity in
chemical structure to other known AC inhibitors. Three novel inhibitors identified show
varying isoform selective inhibition of AC.
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Figure 7: Predicted Binding Conformation and Characterized Isoform Selectivity of
Novel AC Inhibitor CB-6673567. (A) Chemical structure of novel AC inhibitor CB6673567. (B) Isoform selective AC inhibition by CB-6673567. 15µg of membranes of
indicated AC isoform stimulated by 50µM forskolin, incubated with indicated
concentration of inhibitor. p < 0.05 for *, p < 0.01 for **, p < 0.001 for ***. (C) Predicted
binding conformation of CB-6673567 (cyan carbons) in AC catalytic site by Glide
docking program. C1 domain is yellow, C2 domain is silver, manganese metal ion is
orange. (D) Predicted binding conformation of CB-6673567 (cyan carbons) with AC
catalytic site residues within 3.5 angstroms displayed (grey carbons).
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Figure 8: Predicted Binding Conformation and Characterized Isoform Selectivity of
Novel AC Inhibitor CB-7833407. (A) Chemical structure of novel AC inhibitor CB7833407. (B) Isoform selective AC inhibition by CB-7833407. 15µg of membranes of
indicated AC isoform stimulated by 50µM forskolin, incubated with indicated
concentration of inhibitor. p < 0.05 for *, p < 0.01 for **, p < 0.001 for ***. (C) Predicted
binding conformation of CB-7833407 (cyan carbons) in AC catalytic site by Glide
docking program. C1 domain is yellow, C2 domain is silver, manganese metal ion is
orange. (D) Predicted binding conformation of CB-7833407 (cyan carbons) with AC
catalytic site residues within 3.5 angstroms displayed (grey carbons).
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Figure 9: Predicted Binding Conformation and Characterized Isoform Selectivity of
Novel AC Inhibitor CB-7921220. (A) Chemical structure of novel AC inhibitor CB7921220. (B) Isoform selective AC inhibition by CB-7921220. 15µg of membranes of
indicated AC isoform stimulated by 50µM forskolin, incubated with indicated
concentration of inhibitor. p < 0.05 for *, p < 0.01 for **, p < 0.001 for ***. (C) Predicted
binding conformation of CB-7921220 (cyan carbons) in AC catalytic site by Glide
docking program. C1 domain is yellow, C2 domain is silver, manganese metal ion is
orange. (D) Predicted binding conformation of CB-7921220 (cyan carbons) with AC
catalytic site residues within 3.5 angstroms displayed (grey carbons).
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Chapter 5
NKY80 Docking and Full Characterization of AC
Isoform Selectivity
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History of NKY80 Inhibitor
Based on the structure of the cell permeable, AC5 selective P-site inhibitor SQ22536,
NKY80 was developed in order to produce a similarly selective inhibitor with a structure that
did not contain an intact adenine ring. This is due to concern over off-target effects involving
inhibition of DNA polymerases, kinases, and ATP synthases. NKY80 maintains an adeninelike motif at the C2 and C6 carbons that was accurately predicted to be essential for AC5
inhibitors[104]. However, the adenine ring in NKY80 is modified elsewhere, eliminating DNA
synthesis inhibition as a potential off-target effect. NKY80 shows inhibition for AC5 with a Ki
in cell-free assays of 8.3µM[104]. This inhibition is more potent compared to the ability of
NKY80 to inhibit AC3 (16-fold) and AC2 (200-fold) [104], and thus may serve as a good
template for the development of other AC5 inhibitors. Like its P-site inhibitor predecessors,
NKY80 is also not a competitive inhibitor[104]. However, while it is derived from a cell
permeable AC inhibitor, NKY80 was not effective when tested in a cell-based assay[105].
Reasons for membrane impermeability based on the chemical structure of NKY80 are not
apparent. Additionally, its potential for inhibiting isoforms other than AC2, AC3, or AC5 has
not been characterized. Regardless, for research NKY80 is currently considered a standard for
selective small molecule inhibition of AC5.

NKY80 Docking to AC
Classic P-site inhibitors bind with an adenine group in the “A” pocket, a multiphosphate group in the metal-containing “B” pocket, and a connecting ribose or ribose-like ring
group. This binding position supported in the literature has been replicated as part of validating
the computational structure of the AC catalytic site that was developed as a docking target for
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small molecule AC inhibitors. NKY80 is an optimized small molecule inhibitor originally
derived from the structure of a P-site inhibitor, and has been shown previously to have a
selectivity characteristic that classic P-site inhibitors do not have. In order to determine the AC
structural interactions that could explain this unique selectivity, NKY80 was docked to the AC
structure with AutoDock (Figure 10). The adenine-modified chemical group of NKY80 bound
to the “A” pocket. However, NKY80 has no phosphates to interact with metal ions in the “B”
pocket as shown by P-site inhibitors, either directly or indirectly with pyrophosphate. The
clearest difference of NKY80 to 2’,3’-dd-ATP is in the ring region between the “A” and “B”
pockets. 2’,3’-dd-ATP has a ribose ring that, while having some potential for intermolecular
interaction, more notably serves as a connector between high affinity phosphate-metal
interactions and “A” pocket interactions that block off the binding region for an adenine base.
The furan ring of NKY80 instead shows a substantial shift towards Asn1025 on the C2 domain
of AC. This shift brings a likely potential hydrogen bond between NKY80 and Asn1025 within
a bond distance of 2.9 Å. Although its sole importance cannot be verified by this method, this
result does suggest a strong role for Asn1025 in AC inhibition by NKY80. It is unclear if this
interaction explains the selectivity profile of NKY80, or how it is able to inhibit at the catalytic
pocket at nanomolar concentrations despite lacking a phosphate or polyphosphate group.

Comparison of NKY80 Inhibition of AC5 and AC6
In previous NKY80 characterizations, NKY80 had its inhibition potency for AC5
compared to AC2 and AC3[104]. In order to determine how truly selective the NKY80
molecule is, the inhibition capability of AC5 was compared to AC6, the two most closely
related AC isoforms, in an AC activity assay (Figure 11A). AC5 was marginally more potently
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Figure 10: Predicted Binding Conformation of NKY80. (A) Chemical structure of AC
inhibitor NKY80. (B) Predicted binding conformation of NKY80 (cyan carbons) in AC
catalytic site by AutoDock 4.2. NKY80 conformation is an overlay with of 2’,3’dd-ATP
conformation (grey carbons) as reference. C1 domain is yellow, C2 domain is silver,
manganese metal ion is orange. (C) Predicted binding conformation of NKY80 (cyan
carbons) with AC catalytic site residues within 3.5 angstroms displayed (grey carbons).
inhibited than AC6 at each concentration of NKY80 used. This is shown by observed IC50 of
7.1µM for AC5 compared to 17µM for AC6, an approximately 2.5 fold difference. This
potency shift was generally not significant at equivalent concentrations of NKY80, and it can
be concluded that AC5 and AC6 are similarly inhibited by NKY80.
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NKY80 Inhibition Curves for AC 1-9
With NKY80 shown to not have perfect AC5 isoform specificity, all 9 AC isoforms
were tested in AC activity assays with NKY80 to determine how truly selective the small
molecule inhibitor was (Figure 11B). AC1-7 were expressed in Sf9 membranes; as AC8 and
AC9 do not express well in Sf9 membranes, expression in HEK membranes was instead used
for these two isoforms. Results show that NKY80 inhibition of AC5 and AC6 is much more
potent than inhibition of all other isoforms. There appears to be an intermediate potency group
of AC1, AC3, and AC4, as well as a low potency group including AC2, AC7, AC8, and AC9.
Unlike the more strongly inhibited AC5 and AC6 isoform group, these two other groupings do
not follow the typically categorized AC isoform families with evolutionary similarity and
higher overlap in regulators. Observed IC50 for AC2, AC3, and AC5 agree with previously
published results[104], and interestingly the docking score for NKY80 to the 1CJT AC derived
structure predicted affinity of NKY80 for AC was very close to the inhibition potency of
NKY80 for AC5 (Table 2).

Summary
The small molecule AC inhibitor NKY80 was docked to AC structure with AutoDock
4.2, and its concentration-dependent ability to inhibit all 9 AC isoforms was characterized
experimentally. Despite being advertised as an AC5 selective inhibitor, NKY80 also strongly
inhibits the closely related isoform AC6. When compared to nonselective P-site inhibitors, the
ring structure of NKY80 moves towards a predicted hydrogen bond with AC residue Asn1025.
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Figure 11: Full AC Isoform Selectivity Characterization of NKY80. (A) Concentration
curves of AC5 and AC6 inhibition by NKY80 from a representative experiment. 15µg of
membranes of indicated AC isoform stimulated by 50µM forskolin, incubated with
indicated concentration of inhibitor. p < 0.05 for *. (B) Concentration curves of NKY80
inhibition of transmembrane AC isoforms. 15µg of membranes of indicated AC isoform
stimulated by 50µM forskolin, incubated with indicated concentration of inhibitor. AC
isoform family is indicated by color of the inhibition curve; Group I AC’s are red (AC1
= red, AC3 = dark red, AC8 = light red), Group II AC’s are green (AC2 = green, AC4 =
dark green, AC7 = light green), Group III AC’s are blue (AC5 = blue, AC6 = cyan), AC9
is grey.
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Chapter 6
Discussion

42

AC Isoform Groups and NKY80 Selectivity
It was expected that NKY80 selectivity for inhibiting AC isoforms would follow classic
AC groups that are phylogenetically related and have closer patterns of regulation. These are
Group 1 (AC1, AC3, and AC8), Group 2 (AC2, AC4, and AC7), Group 3 (AC5 and AC6), and
Group 4 (AC9)[6]. Consistent with this prediction, NKY80 inhibited AC5 and AC6 much
better than the other isoforms. However, the other inhibition curves surprisingly did not show
separation of Group 1 and Group 2 AC isoforms. AC1, AC3, and AC4 had NKY80 IC50 in the
high micromolar range, consistent with the previously published AC3 IC50 of approximately
132µM. AC2, AC7, AC8, and AC9 had NKY80 IC50 somewhere beyond the 1mM
concentration tested. The IC50 of AC2 has previously been published to be about 1.2 mM; we
assume that AC7, AC8, and AC9 remain on a similar inhibition curve beyond 1mM as AC2.
These groupings also do not follow known similarities in AC isoform regulation. Lack of
known isoform similarity for these groupings combined with the observed 10-fold differences
in NKY80 inhibitory potential between AC isoforms being possible from minor changes in AC
spatial conformation, the prospect of explaining the catalytic structure differences between the
AC1/3/4 and AC2/7/8/9 groups seems unlikely. Determining why NKY80 inhibits AC5 and
AC6 better than the remainder of AC isoforms is more probable, considering the greater
similarity of these two AC isoforms.
Although NKY80 is described as an AC5 selective inhibitor, it strongly inhibits both
AC5 and AC6. Supposed AC5 selectivity issues are not just restricted to AC inhibitors. The AC
catalytic site is pseudosymmetrical, and the binding pocket for the AC activator forskolin is
found opposite to the ATP binding site. Novel AC selective small molecule activators derived
from forskolin have been developed that show selectivity for cardiac AC5 over AC2 and AC3,
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but were not tested against the closely related AC6[106]. One of the activators developed is
clinically approved for acute heart failure, colforsin daropate[71]. Considering the beneficial
effects from AC6 activation for chronic heart failure, it seems reasonable to consider if
colforsin daropate stimulates AC6 as well as AC5.

AC Catalytic Site Residues and Inhibitor Selectivity
Asn1025 is a residue in the catalytic site of AC that virtual docking of NKY80 suggests
is involved in the ability of NKY80 to bind at the AC catalytic pocket. Asn1025 is conserved in
all 9 isoforms, so why it would confer isoform selectivity to NKY80 is not immediately clear
by a difference in isoform sequence. Thus, it is unclear if the cause for this residue’s interaction
with NKY80 is directly due to the residue or residue type, or if the interaction is induced by an
isoform specific allosteric effect. However, it is clear that Asn1025 location or placement is
important for NKY80 binding.
It is known that NKY80 is somewhat isoform selective, with a preference for inhibition
of AC5[104] and, apparently, AC6. It is noteworthy that P-site inhibitors are one of two larger
families of classic AC small molecule inhibitors. The other is MANT-nucleotide analogs of
ATP. MANT-GTP and similar inhibitors share an increased inhibitory potency for AC5 and
AC6, although with a less profound difference between these isoforms and others. The MANT
group on these molecules, for example with MANT-GTP, binds to AC based on a crystal
structure where there is structural helix movement to allow a new pocket that we shall call a
“C” pocket in addition to the “A” and “B” inhibitor binding pockets used by P-site
inhibitors[84]. The beginning of the opening to this extra “C” pocket, consisting of the α1 helix
of the C1 domain and the α4’ helix of the C2 domain, lies just beyond Asn1025. The large
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movement of these two helices accommodates the hydrophobic region which interacts with the
MANT group, as seen when comparing the 1CJT and 1TL7 AC structures (Figure 12A).
Hydrophobic region opening also includes significant movement of the sidechains for Thr401
and Asn1025, the residues noticed as possible causes for the selectivity of the novel AC1
inhibitors and NKY80 respectively. This is also supported by the α1 helix having isoform
specific residue variability that is rare to find in the AC catalytic site (Figure 12B). More
flexibility for AC5 and AC6 in this subregion would increase entropy, and thus make
interaction of the subregion residues with inhibitors more energetically favorable. Thus,
NKY80 and MANT-attached nucleotides may similarly interact with AC in this mobile
subregion of the catalytic site conferring similar AC5 and AC6 selectivity.
Sites unique to the C1/C2 domains of AC5 and AC6 are not without precedence. The
AC5/6 C1 domains both have a binding site for Giα, for example[107]. However, such
regulatory sites can usually be identified in the AC primary sequence. Instead, in the case of
NKY80 and MANT-GTP, it is possible that the AC5/6 isoform family is more flexible in this
catalytic subregion bracketed by the α1 and α4’ helices, and thus more accommodating to
stable conformations with interactions by these small molecule inhibitors.
NKY80 is similar in selectivity to the competitive inhibitor MANT-GTP, but is derived
from uncompetitive P-site inhibitors. As NKY80 is also not a competitive inhibitor, this
supports the development of novel isoform selective inhibitors that also do not have a
competitive mechanism. As previously mentioned, one of the justifications for using P-site
inhibitors as a template for a desired AC isoform selective therapeutic as opposed to MANTnucleotides is the desire for an uncompetitive inhibitory mechanism. Uncompetitive inhibition
causing decreased maximal cAMP concentrations capable by cardiac AC5 as a chronic heart
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Figure 12: Structural Flexibility in the AC Catalytic Site. (A) Overlay of crystal
structures of AC catalytic site from 2’,3’-dd-ATP (PDB ID 1CJT; C1 = yellow, C2 =
silver) and MANT-GTP (PDB ID 1TL7; C1 = tan, C2 = black). Manganese metal ion is
orange and labeled. Positions of Thr401 and Asn1025 indicated for 1CJT with cyan
carbons, for 1TL7 with grey carbons. The α1 and α4’ helices of AC are also labeled. (B)
Primary sequence alignments for α1 and α4’ helix domains of crystal AC structure,
human AC’s 1-9. Residues that differ from the primary sequence of the 1CJT crystal
structure C1/C2 domains are red. Residue Thr401 in the AC C1 sequence alignment is
blue. Residue Asn1025 in the AC C2 sequence alignment is green.
failure treatment, for example, would still allow lower levels of cAMP activity. Thus, such a
mechanism would likely make long term treatment easier by not shutting down AC5/cAMP
46

pathways completely. By contrast, a competitive inhibitor’s safe dosage could be more
sensitive to local concentrations of ATP. It will be of great interest to determine what
mechanism is used by selective AC inhibitors produced by optimization of the novel
ChemBridge inhibitors that have been identified.

Chemical Groups Important for NKY80 Inhibition of AC
There are two main differences between NKY80 and classic P-site inhibitors in
chemical structure that are apparent when comparing their binding conformations. One, as
previously mentioned, is hydrogen bonding of the NKY80 furan ring with Asn1025, which
involves a movement of that ring away from where a P-site inhibitor’s ribose ring is oriented.
This could explain both a phosphate-less nanomolar potency for NKY80 and/or the inhibitor’s
selectivity, as it is the beginning of a catalytic site subregion with flexibility that may
accommodate isoform specific interactions. Crystal structures of AC with bound MANTnucleotide inhibitors where the MANT group interacts in this subregion support such a
claim[84]. Additionally, the slight selectivity in P-site inhibitor derived compounds for AC5
was first noticed when the ribose ring of classic P-site inhibitors was modified to a furan ring to
create the small molecule inhibitor SQ22536[104]. This suggests further that interaction of a
furan ring with the catalytic residue Asn1025 is a significant part of the explanation for the
observed AC5/AC6 inhibitor selectivity for NKY80 and structurally related selective
compounds. Modifications to the furan ring of NKY80 resulting in a decrease in NKY80
potency also support this chemical group’s importance for inhibitor potency in the absence of
phosphates, research that was notably done with an aim of targeting cardiac AC5[105].
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Regrettably, many small molecule AC inhibitors have not been characterized for inhibition
potency of both AC5 and AC6.
The other noteworthy difference between NKY80 and classic P-site inhibitors is the
carbonyl group of NKY80. This chemical property of NKY80 is more closely related to the
structure of guanine or inosine based inhibitors such as MANT-GTP and MANT-ITP, as
opposed to adenine based inhibitors such as MANT-ATP or the classic P-site inhibitors. Based
on its predicted binding position, the carbonyl oxygen points out into what is essentially open
space; there is no clearly interacting AC residue within 3.5 Å. By comparison, MANT-GTP has
a hydrogen bond between its carbonyl and AC residue Lys938 in the “A” pocket[84].
Additionally, no residues appear to be significantly closer to this group than they would be to a
similar oxygen-containing group in the P-site inhibitor structure. It is possible that other effects,
such as solvation with water molecules, could allow this carbonyl to interact with residues
further away in the AC catalytic site, conferring inhibitor potency and/or AC isoform
selectivity. As these docking experiments were done in the absence of water, it cannot be
currently determined if there is such a solvation effect.

Comparison of NKY80 to Other AC Inhibitors
HTS09836, as previously mentioned, is a patented AC1 selective inhibitor[103, 108]. In
Asia it is an orally available analgesic treatment. It is capable of crossing cell membranes, a
significant obstacle in the development of classic P-site inhibitors and MANT-nucleotides as
therapeutics. NKY80 is reported not to work in cell-based assays. This is surprising as the
extremely similar inhibitor it is derived from, SQ22536, is slightly less selective but despite an
intact adenine ring can inhibit AC activity in cells[105]. However, this maintained adenine ring
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eliminates SQ22536 from further therapeutic development, as the off-target effects on DNA
synthesis that are possible are greatly undesired for a specific drug.
Small molecule inhibitors of AC such as tryphostins and catechol oestrogens offer an
alternative to the more well characterized P-site inhibitors and MANT-nucleotide inhibitors as
drug development templates, and these molecules appear to have some isoform
specificity[102]. However, their binding site is distinct from the ATP binding position used by
P-site inhibitors and MANT-nucleotides, and they require direct interaction with metal ions. To
date, published inhibitors using this pocket have only targeted sAC and can differentiate
between the 9 membrane-bound isoforms of AC and sAC[109]. Nonetheless, some small
molecules derived from P-site inhibitors show promise with integrating these metal chelating
properties and isoform selectivity, such as PMC-6[100]. Combining the best inhibitor
characteristics of PMC-6 and NKY80 may be the path ahead for making therapeutic inhibitors
that preferentially target AC5 and/or AC6.
Although it turns out that NKY80 strongly inhibits both AC5 and AC6, other inhibitors
at the catalytic site are capable of inhibiting one of these closely related isoforms better than the
other. The small molecule inhibitor 2’-d-3’-MANT-GDP has a Ki for AC1 at 1.7 nM and AC6
at 3.1 nM, while AC2 and AC5 Ki were determined to be 21 and 25 nM respectively[83].
Reported AC5 inhibitors that do not inhibit AC6 include the antiviral drug Ara-A (also known
as vidarabine). Although used originally as an FDA-approved antiviral, Ara-A has recently
become of interest in cases of chronic heart failure. Ara-A shows some selectivity for inhibiting
AC5 but not AC6 at a concentration of 10uM in cardiomyocyte membranes and intact
cells[110, 111]. Its mechanism and inhibitory profile in comparison to NKY80 is of great
interest, as the two are structurally similar.
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Cardiac Complexes of AC5/AC6 and Inhibitor Selectivity
Preliminary results indicate that it cannot be ruled out that Ara-A’s effects are specific
to the cardiac cell type. Although not completely surprising considering its great similarity to
adenosine and already characterized effect as an antiviral drug, off-target effects are not the
only possible explanation for cell-specific Ara-A effects. It may also be that AC5 and AC6
cardiac complexes in a chronic heart failure setting have cell and isoform specific regulation
that affect baseline isoform activity, showing greater % inhibition for AC5 from Ara-A and
similar compounds.
If cardiac specific AC complexes are influencing AC5/AC6 inhibitor sensitivity, the
specificity of signaling complexes including AC are further supported as being important for
regulation of AC and the resulting local pools of cAMP. One example is those complexes
formed by A-kinase anchoring proteins (AKAPs). AKAPs all anchor protein kinase A (PKA)
as well as a more AKAP-specific complement of other kinases and phosphatases. AKAP
complex-dependent kinase activity has been shown previously[112]. In addition, AKAP
complexes with specific AC isoforms have been shown in cardiac cell types[45, 113-116]. The
ability of EGF to increase cAMP accumulation in cardiomyocytes but not non-cardiac cells
expressing a similar complement of AC isoforms further supports differences in cell specific
AC isoform complexing[117]. Compartmentalized cAMP production in cardiac cells as would
be expected has been previously shown[118], along with dynamic changes in the cAMP pool
due to upstream adrenergic receptor specific signaling[119]. Effects of cell and isoform specific
regulatory signaling complexes could explain the differences in selectivity seen for allegedly
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AC5 selective inhibitors related to NKY80 in different assays, such as PMC-6[105] and AraA[110, 111].
It is also possible that heterodimerization of AC isoforms may be an influence on
perceived isoform selective inhibition. It has been suggested for some time that dimerized AC
exists, both through biochemical[120] and FRET-based[121] methods. AC associates in
dimeric complexes through their transmembrane domains, as has been shown for AC6[122].
AC5 cooperativity in Gsα stimulation differs from Michaelis-Menten kinetics for stimulation of
AC6[24]; it has been suggested that this can be explained by AC5 dimerization both in that
work and elsewhere[123]. In cardiac complexes, one possible explanation could be that AC5
expression models involve homodimers, whereas AC6 expression in the same cardiac cells
results in heterodimerization with an AC isoform less sensitive to inhibitors such as NKY80 or
Ara-A. Thus, cardiac models produced by AC5 overexpression would be much more sensitive
to these compounds than those produced by AC6 overexpression.
There is physiological precedence for differences between AC5 and AC6 regulation that
are tissue dependent. Nitric oxide indirectly inhibits both AC5 and AC6 in N18TG2 cell
membranes[124], but only inhibits AC6 in COS-7 cells[125]. Supporting that such regulation
differs due to tissue-dependent AC5 and AC6 specific signaling complexes, it has also been
shown that localization to caveolae is required for nitric oxide mediated inhibition of AC6 in
cardiomyocytes[126]. Cardiac caveolae-based complexes are also required for the organization
of different forms of AC5 regulation, including calcium inhibition by capacitative Ca2+
entry[127] and stimulation by upstream GPCRs[128].
The main implications tissue-dependent AC complexes would have for development of
a small molecule inhibitor with therapeutic potential are twofold. First, tissue selectivity could
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be derived for an AC inhibitor by targeting tissue specific complexes. Second, separating AC5
and AC6 selectivity in a small molecule inhibitor would not be necessary as long as the
differences in AC5 and AC6 cardiac complexes influencing their inhibition sensitivity were
known.

Future Directions
With the possible furan and carbonyl moiety trends for AC5 selectivity in NKY80, AraA, and similar discovered novel AC inhibitors, drug optimization using these chemical groups
can be used to determine their necessity for potent inhibition of AC and/or isoform selectivity.
Additionally, using the crystal structure of MANT-GTP bound to AC, the screen for novel AC
inhibitors can be repeated to see what small molecules overlap and bind tightly in both
structures, as well as which novel inhibitors are predicted to interact in the novel “C” pocket
where MANT binds. This will be particularly critical for determining isoform selectivity
characteristics of the novel ChemBridge inhibitors. Their predicted binding positions showed
no clear reasons for selectivity, but a second AC conformation may provide a better fit for the
predicted binding position of these compounds and better explain their observed isoform
selectivity.
Such inhibitors can be further optimized by searching the ChemBridge virtual screening
results for structurally similar ligands that can also be tested for AC inhibition. Additionally,
other drug-like small molecule libraries can be tested with a more focused effort on identifying
AC inhibitors with chemical groups that give isoform selectivity, such the furan ring that is part
of NKY80. In order to better explore the capability of inhibitors to pass the cell membrane and
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work in human cells to inhibit cAMP production, the novel inhibitors already identified and
any more found from optimized screens should also be tested in cell-based assays.
Lastly, it is worth noting that the crystal structures being used, although equivalent to
human AC5 at the catalytic site, are not the same throughout their amino acid sequence. Should
a structural model be crystallized with human C1/C2 domains, dynamic docking of inhibitors
with known or produced isoform selectivity profiles can be performed to better observe flexible
changes in AC structure that may confer isoform selective characteristics.

Summary
Although conserved across all AC isoforms, structural flexibility may allow AC residue
Asn1025 to confer AC5/6 selectivity to the small molecule inhibitor NKY80. Targeting of
Asn1025 and the large hydrophobic patch behind it between the α1 and α4’ helices may be
useful for producing isoform selective AC inhibitors, and to understand subtle differences
between the AC isoforms in the well conserved catalytic area.
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